One of the most interesting aspects on Dr. Lucire's research is in the area of phamacokinetics. This is one of the most critical elements of research which defines the toxicity potential of any drug. It it primarily concerned with the bodily absorption, distribution, metabolism and excretion of ingredients within a specific drug. What is suprising is that more than 99% of all pharmaceutical drugs and vaccines have absolutely no conclusive or long-term phamacokinetic research to validate any clinical trials of any drugs in human beings.
"If Dr. Lucire's research were to be taken seriously, it would revolutionize the way Physicians treat patients," said Naturopathic Doctor, Dr. Dave Mihalovic. "The reason that pharmacokinetic research is rarely if ever properly evaluated throughout any clincial trial is because drug manufacturers know that it would offer conclusive evidence that almost every drug and vaccine available today is cytotoxic, hepatotoxic and organotoxic to all living organisms, not just humans."
Dr Lucire has been campaigning to introduce systematic doctor education in order to minimize promiscuous and uninformed anti-depressant prescribing. With her complaints, findings and warnings about lack of action, Dr Lucire has been assiduously lobbying her colleagues, the Medical Board and the Health Care Complaints Commission of NSW, the Adverse Drug Reactions Advisory Committee (ADRAC) of the federal Therapeutic Goods Administration in Australia and a clutch of ministers, both state and federal, for many years. Most recently she has been providing redacted files on her own extensive sample of DNA swab-tested relapsing patients suffering from the side effects of serotonin reuptake inhibitors (SSRIs) and polypharmacy.
She has been on a mission, fighting back against the Pharma-driven psychiatric consensus that treating with SSRIs is safe and effective, working hard to wean patient-victims as well as their prescribers off the drugs.
Very often Big Pharma itself has largely conjured up the booming markets in which its dubious drugs offer expensive treatment for dubious medical conditions. The biggest and most lucrative scandals have been in two types of second-generation drugs: anti-depressants or SSRIs - Prozac, Paxil, Zoloft, etc, and "atypical" antipsychotics such as Zyprexa, Risperdal and Seroquel which were known from their licensing to be ineffective for the vast majority of clinical trial subjects and up to twice as bad for inducing suicide as antidepressants.
The corrupt drug trial and marketing practices of Big Pharma include imaginary science (the serotonin deficiency theory of depression), systematic suppression of lethal side effects (akathisia - cannot-sit-down restlessness - leading to suicidal ideation, suicide and murder) and a multi-billion dollar success over the past generation in medicalising the ordinary ups and downs of the human psyche.
Feeling sad? ("Moderate depression", worthy of a happy little Zoloft rock.) Diffident? ("Social anxiety disorder", try Aropax.) If antidepressants cured any significant number of people there would be significantly less cost and less demand for mental health services in Australia. Whether from inadequate or tendentious pharmacology training, laziness, busyness, greed driven by willed ignorance or even misplaced conviction, the medical profession has succumbed to the cynical marketing and the targeted blandishments of the pharmaceutical companies.
Medical and scientific journals from Nature to The New England Journal of Medicine allowed their columns to be infiltrated for years by blatantly dishonest research reporting and ghost written articles commissioned in Pharma-land but signed by distinguished professors frequently in receipt of seven-figure research and consultancy funding. Most of these journals do now take another tack, debunking Pharma claims and exposing fraudulence. But many medical professional bodies are still being subsidised beyond hope of objective dealing with the issue of mass iatrogenesis caused by dud drugs andmultiple drug prescribing ("polypharmacy"), and particularly with the lethal side effects of anti-depressants.
The key drug regulator in the US - and the planet - the United States Food and Drug Administration (US FDA) has failed to purge the Pharma-friendly experts who have dominated its rulings up to now. Our own Therapeutic Goods Administration obediently follows suit, also licensing drugs largely on information provided by their makers. But in America the going has been getting perceptibly harder for the drug companies.
According to the New York Times, Dr Joseph Biederman, the pioneer of "aggressive diagnosis and drug treatment of childhood bipolar disorder", failed to report most of the $1.6 million he received in pharma funding over several years while at Harvard.
Part of the controversy stemming from Dr. Lucire's research is cytochrome P450 genotyping which is the study of a large and diverse group of enzymes.
CYP2D6 (cytochrome P450 2D6) acts on one-fourth of all prescription drugs, including the selective serotonin reuptake inhibitors (SSRI), tricylic antidepressants (TCA), betablockers, opiates, neuroleptics, antiarrhythmics and a variety of toxic plant substances. Up to 15% of the population has a slow acting form of this enzyme and many of these a fast-acting form. Thirty-five percent are carriers of a non-functional CYP2D6 allele, especially elevating the risk of adverse drug reactions when these individuals are taking multiple drugs. Drugs that CYP2D6 metabolizes include Prozac, Zoloft, Paxil, Effexor, Hydrocodone, Amitriptyline, Claritin, Cyclobenzaprine, Haldol, Metoprolol, Rythmol, Tagamet, Tamoxifen, and the over-the-counter diphenylhydramine drugs, Allegra, Dytuss, and Tusstat. CYP2D6 is responsible for activating the prodrugs codeine and other opioids into their active forms. The analgesic activity of the drugs is therefore reduced or absent in CYP2D6 poor metabolizers. The following is a full list of drugs that need the 2D6 pathway to metabolize.
This means that potentially up to 1 billion people on the planet cannot metabolize and eliminate the commonly prescribed drugs from their bodies as others without enzyme inhibition would. Since the genetic polymorphism in CYP2D6 is common, it can affect therapeutic response to these drugs and actually worsen specific conditions.
CYP2D6 metabolism, as measured by genetic variation and enzyme inhibition, is also an independent predictor of breast cancer outcomes. Determination of CYP2D6 genotype may be of value in selecting alternative therapies and it appears CYP2D6 inhibitors should be avoided in many women treated via pharmaceutical intervention.
The National Coalition of Organized Women (NCOW) has stated that the information that would have averted the school shootings, the homicides, the overdoses, the bizarre epidemic of mentally ill in recent years has been available for circa 15 years. But it has been suppressed so that the stake holders might find alternative drugs that use other than 2D6 as the metabolic pathway. Cytochrome P450 2D6 is the metabolic pathway that detoxifies 50% of all psyche drugs and street drugs. 7-10% of Caucasians are missing the 2D6 pathway to detoxify 50% of psyche drugs and street drugs. Check out this most egregious cover up in the history of modern psychiatry. Dr. Lucire illucidates. Her study just published in the summer of 2011 is not only a academic victory but the homicidal speak of their experiences in their own words on how they were moved to kill their loved ones.
Eileen Dannemann. Director of NCOW stated "the interesting thing I found was that the glutathione pathway implicated in vaccine injury/ Autism Spectrum is found on the same cytochrome 450. Vaccines are so toxic that if someone is a poor metabolizer they will sustain a vaccine injury; then get misdiagosed as ADHD, ADD, etc and then given harmful life debilitating drugs."
Some treatment protocols for autistic children now include support for cytochrome P450 detoxification enzymes. These include natural remedies such as milk thistle, ginger, dandelion, turmeric, and phosphatidylcholine.
Despite a large number of studies investigating the potential clinical relevance of CYP2D6 genotyping in preventing treatment failure (eg, insufficient efficacy and/or unacceptable adverse effects), the prevalence of patients using drugs metabolized by that enzyme is relatively unknown. However, it is clear that several patient populations in developed nations (eg, psychiatric, psychogeriatric, geriatric) have a high prevalence of patients treated with at least one drug metabolized by CYP2D6. Theoretically, assumptions can be made that these patients would inevitably be exposed to toxic levels of these drugs due to poor metabolism. If left undiagnosed, drug treatment could lead to additonal misdiagnoses and could prove fatal for many patients.